SHEMILA FASIHI: Open Payments
NPI 1033952627 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$245 in 6 payments from 5 companies in 2025. Trend: 2023 $0 · 2024 $234 · 2025 $245
Food & beverage: $245
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 1 | $106 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $49 |
| Veloxis Pharmaceuticals, Inc. | 1 | $38 |
| Ethicon US, LLC | 1 | $28 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
Products named: ULTOMIRIS, XIFAXAN, ENVARSUS, PROLENE, OCALIVA.
Industry payments across DC — which companies pay providers there.
